{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-271071","form_type":"8-K","ticker":"LYEL","cik":"0001806952","company_name":"Lyell Immunopharma, Inc.","filed_at":"2026-06-15T20:05:50+00:00","discovered_at":"2026-06-15T20:07:00.269149+00:00","generated_at":"2026-06-15T20:16:19.219751+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Lyell Immunopharma shareholders elect three directors, ratify EY, approve say-on-pay at 2026 annual meeting","bullets":["Quorum of 67.31% (15,706,826 shares) present; all three proposals passed.","Elected Class II directors Richard Klausner, Otis Brawley, William Rieflin with >99.2% of votes cast in favor each.","Ratified Ernst & Young as independent auditor for FY2026: 15,674,347 for, 30,758 against, 1,721 abstain.","Advisory vote on named executive officer compensation passed: 11,860,218 for, 6,613 against, 410,709 abstain, 3,429,286 broker non-votes."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-271071","json":"https://secwatch.observer/filing/0001193125-26-271071.json","markdown":"https://secwatch.observer/filing/0001193125-26-271071.md","text":"https://secwatch.observer/filing/0001193125-26-271071.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806952/000119312526271071/0001193125-26-271071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806952/000119312526271071/d102015d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T20:16:19.219751+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"32b56b2201169158c72a25b01e2c0554a4208660","claim":"Lyell Immunopharma, Inc. shareholders approved Advisory vote on the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement at the 2026-06-10 meeting.","evidence_excerpt":"To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes Total 11,860,218 6,613 410,709 3,429,286 15,706,826","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312526271071/0001193125-26-271071-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-10"}],"fact_type":"shareholder_vote"},{"claim_id":"ac96924132db81d345552d0e1dcc9997b5a92fcf","claim":"Lyell Immunopharma, Inc. shareholders approved Election of Class II directors to hold office until the Company's 2029 annual meeting of stockholders at the 2026-06-10 meeting.","evidence_excerpt":"To elect the following Class II directors to hold office until the Company’s 2029 annual meeting of stockholders. The voting results were as follows: Name Votes For Votes Withheld Broker Non-Votes Total Richard Klausner, M.D. 12,177,913 99,627 3,429,286 15,706,826 Otis Brawley, M.D. 11,866,210 411,330 3,429,286 15,706,826 William Rieflin 12,192,547 84,993 3,429,286 15,706,826","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312526271071/0001193125-26-271071-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-10"}],"fact_type":"shareholder_vote"},{"claim_id":"f516b585021a182e2a1aea7c48021be30369bcaa","claim":"Lyell Immunopharma, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-10 meeting.","evidence_excerpt":"To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The voting results were as follows: Votes For Votes Against Abstentions Total 15,674,347 30,758 1,721 15,706,826","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312526271071/0001193125-26-271071-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-10"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}